GlassScriptPhysician profile
Caroline Tan
NPI 1750842134
$7,277.83
in general payments reported to CMS, 2019-2025
25 companies · $3,308 in 2025
The $3,308 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.23 · 2023: $919 · 2024: $2,986 · 2025: $3,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,795 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,794.53 |
| Education | $372.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.73 | 2023-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $793.08 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $738.28 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $514.02 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $481.00 | 2024-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $420.22 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $370.32 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $335.74 | 2024-2025 | |
| Leo Pharma INC. | $277.56 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Ucb, INC. | $276.67 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $237.22 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $180.29 | 2024 | |
| Amgen INC. | $123.44 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $123.36 | 2023-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.00 | 2023-2024 | Spevigo, Cyltezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $86.59 | 2024 | Puraply Am |
| Organon LLC | $82.10 | 2025 | Vtama |
| Revance Therapeutics, INC. | $77.88 | 2024-2025 | Daxi, Daxxify |
| Novartis Pharmaceuticals Corporation | $68.85 | 2025 | |
| Merz North America, INC. | $65.82 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $34.16 | 2025 | Acthar |
| Fresenius Kabi USA, LLC | $30.93 | 2023 | Idacio |
| Almirall LLC | $28.94 | 2024 | Klisyri |
| Pfizer INC. | $26.65 | 2025 | |
| Verrica Pharmaceuticals INC. | $22.87 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.